Skip to main content

Table 2 Adaptation to normoxia (N) confers a highly proliferative ability to ES2 cells

From: Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer

A.

Treatments – proliferation curve (48 h)

Tukey test sig.

ES2-NN vs ES2-HN

0.000

ES2-NN vs ES2-HH

0.000

ES2-NH vs ES2-HN

0.000

ES2-NH vs ES2-HH

0.001

B.

Treatments – cell cycle analysis

Tukey test sig.

G0/G1 ES2-NN vs ES2-NH

0.02

C.

Treatments – proliferation curve (48 h)

Tukey test sig.

OVCAR3-NN vs OVCAR3-HH

0.036

D.

Treatments – cell cycle analysis

Tukey test sig.

G0/G1 OVCAR3-NN vs OVCAR3-HH

0.006

G0/G1 OVCAR3-NH vs OVCAR3-HN

0.033

G0/G1 OVCAR3-NH vs OVCAR3-HH

0.001

G2/M OVCAR3-NH vs OVCAR3-HH

0.027